Bright's Disease

Bright's Disease

By Yolanda Smith, B.Pharm. Reviewed by Afsaneh Khetrapal, BSc Bright’s disease is a historical term that is not currently in use. It referred to a group of kidney diseases - in modern medicine, the condition is described as acute or chronic nephritis. This article is intended to cover the historical relevance of Bright’s disease, in addition to the characteristic signs and symptoms that were used in the diagnosis and treatment of the condition. Historical Relevance The disease was named after Richard Bright, who was the first to describe the symptoms in 1827. He described 25 patient cases involving dropsy, which is now commonly referred to as edema, and linked them to kidney disease in his Reports of Medical Cases. Following from this, research conducted by Bright and other physicians noted a link to cardiac hypertrophy, which led to the suggestion that stimulation of the heart was involved. One notable case of Bright’s disease was that of Arnold Ehret. His condition was diagnosed as incurable by 24 respected doctors in Europe. However, he eventually cured himself of the disease with the design of The Mucusless Diet Healing System. In Modern Medicine, the term Bright’s disease is no longer in use and is only referenced for historical purposes. This is because the disease is due to a vast range of renal diseases, for which there are no more descriptive terms that can be used. Signs and Symptoms The characteristic signs of Bright’s disease were edema and albumin in the urine, which are also a vital part of many renal conditions in Modern Medicine. The wide range of symptoms that were often reported in patients with Bright’s disease included: Edema



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More